Burkitt lymphoma after solid‐organ transplant: Treatment and outcomes in the paediatric PTLD collaborative
暂无分享,去创建一个
Karen M. Chisholm | C. Mason | Tamara P. Miller | Jeremy D. Rubinstein | Erika Friehling | W. Alperstein | James B Ford | M. Ehrhardt | M. Dalal | L. Marks | Z. Afify | Holly J Edington | A. Bukowinski | M. Orjuela-Grimm | Joanna M Robles | Tonya Ureda | Sarah McCormack | Julie M Rivers | Madison Kavanaugh | Sonika Reddy | C. M. Smith | Pallavi M Pillai
[1] Margaret L. Williams,et al. Burkitt Lymphoma After Cardiac Transplantation: Therapeutic Considerations. , 2021, Journal of pediatric hematology/oncology.
[2] O. Abla,et al. Reducing Treatment Burden Matters in Special Populations With Pediatric B-non-Hodgkin Lymphoma. , 2021, Journal of pediatric hematology/oncology.
[3] M. Vélez,et al. American Society of Pediatric Hematology/Oncology (ASPHO) 2021 Paper and Poster Abstracts. , 2021, Pediatric blood & cancer.
[4] R. Norris,et al. Treatment of posttransplant lymphoproliferative disorder with poor prognostic features in children and young adults: Short‐course EPOCH regimens are safe and effective , 2021, Pediatric blood & cancer.
[5] J. Vagher,et al. Two Clonally Distinct B-Cell Lymphomas Reveal the Diagnosis of XLP1 in a Male Child and His Asymptomatic Male Relatives: Case Report and Review of the Literature , 2021, Journal of pediatric hematology/oncology.
[6] Burkitt Lymphoma: Diagnosis, Risk Factors and Treatment , 2021 .
[7] G. Vassal,et al. Rituximab for High-Risk, Mature B-Cell Non-Hodgkin's Lymphoma in Children. , 2020, The New England journal of medicine.
[8] W. Wilson,et al. Multicenter Study of Risk-Adapted Therapy With Dose-Adjusted EPOCH-R in Adults With Untreated Burkitt Lymphoma. , 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[9] L. Cooper,et al. Long‐term remission in an adult heart transplant recipient with advanced Burkitt’s lymphoma post‐transplant lymphoproliferative disorder after anthracycline‐free chemotherapy: A case report and literature review , 2020, Transplant infectious disease : an official journal of the Transplantation Society.
[10] X. Li,et al. PF719 CLINICAL OUTCOMES OF SOLID ORGAN TRANSPLANT PATIENTS WITH EBV+PTLD WHO FAIL FIRST-LINE RITUXIMAB OR RITUXIMAB PLUS CHEMOTHERAPY: AN ANALYSIS OF GERMAN PTLD REGISTRY , 2019, HemaSphere.
[11] Abstracts from the 51st Congress of the International Society of Paediatric Oncology (SIOP) Lyon, France, October 23-26, 2019. , 2019, Pediatric blood & cancer.
[12] O. Abla,et al. Epidemiology of Non-Hodgkin Lymphomas in Childhood and Adolescence , 2019, Non-Hodgkin's Lymphoma in Childhood and Adolescence.
[13] A. Attarbaschi,et al. Non-Hodgkin's Lymphoma in Childhood and Adolescence , 2019, Springer International Publishing.
[14] E. Giné,et al. Posttransplant monomorphic Burkitt’s lymphoma: clinical characteristics and outcome of a multicenter series , 2018, Annals of Hematology.
[15] D. Haffner,et al. Graft outcomes following diagnosis of post‐transplant lymphoproliferative disease in pediatric kidney recipients: a retrospective study , 2018, Transplant international : official journal of the European Society for Organ Transplantation.
[16] S. Swerdlow. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues , 2017 .
[17] A. Kahn,et al. Contribution of solid organ transplant recipients to the pediatric non‐hodgkin lymphoma burden in the United States , 2017, Cancer.
[18] G. Salles,et al. Response to Rituximab Induction Is a Predictive Marker in B-Cell Post-Transplant Lymphoproliferative Disorder and Allows Successful Stratification Into Rituximab or R-CHOP Consolidation in an International, Prospective, Multicenter Phase II Trial. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[19] S. South,et al. Two Unrelated Burkitt Lymphomas Seven Years Apart in a Patient With X-Linked Lymphoproliferative Disease Type 1 (XLP1). , 2016, American journal of clinical pathology.
[20] G. Verhoef,et al. Post-transplant molecularly defined Burkitt lymphomas are frequently MYC-negative and characterized by the 11q-gain/loss pattern , 2015, Haematologica.
[21] S. Perkins,et al. Revised International Pediatric Non-Hodgkin Lymphoma Staging System. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[22] B. Meissner,et al. Response-Adapted Sequential Immuno-Chemotherapy of Post-Transplant Lymphoproliferative Disorders in Pediatric Solid Organ Transplant Recipients: Results from the Prospective Ped-PTLD 2005 Trial , 2014 .
[23] L. Staudt,et al. Low-intensity therapy in adults with Burkitt's lymphoma. , 2013, The New England journal of medicine.
[24] D. Weisenburger,et al. Burkitt lymphoma risk in U.S. solid organ transplant recipients , 2013, American journal of hematology.
[25] A. Großhennig,et al. Characteristics of Early and Late PTLD Development in Pediatric Solid Organ Transplant Recipients , 2013, Transplantation.
[26] J. Lynch,et al. Low‐Dose Chemotherapy and Rituximab for Posttransplant Lymphoproliferative Disease (PTLD): A Children's Oncology Group Report , 2012, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.
[27] D. Lenze,et al. Burkitt post‐transplantation lymphoma in adult solid organ transplant recipients , 2012, Cancer.
[28] G. Salles,et al. Sequential treatment with rituximab followed by CHOP chemotherapy in adult B-cell post-transplant lymphoproliferative disorder (PTLD): the prospective international multicentre phase 2 PTLD-1 trial. , 2012, The Lancet. Oncology.
[29] S. Perkins,et al. Advanced stage, increased lactate dehydrogenase, and primary site, but not adolescent age (≥ 15 years), are associated with an increased risk of treatment failure in children and adolescents with mature B-cell non-Hodgkin's lymphoma: results of the FAB LMB 96 study. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[30] G. Mazariegos,et al. Post‐transplant Burkitt lymphoma is a more aggressive and distinct form of post‐transplant lymphoproliferative disorder , 2011, Cancer.
[31] M. Orjuela,et al. CD20 expression predicts survival in paediatric post‐transplant lymphoproliferative disease (PTLD) following solid organ transplantation , 2011, British journal of haematology.
[32] W. Wilson,et al. The role of tumor histogenesis, FDG-PET, and short-course EPOCH with dose-dense rituximab (SC-EPOCH-RR) in HIV-associated diffuse large B-cell lymphoma. , 2010, Blood.
[33] R. Kirk,et al. Post cardiac transplantation lymphoproliferative disorder presenting as t(8;14) Burkitt leukaemia/lymphoma treated with low intensity chemotherapy and rituximab , 2009, Pediatric blood & cancer.
[34] G. Klein,et al. Burkitt lymphoma. , 2005, Seminars in cancer biology.
[35] S. Perkins,et al. Excellent survival following two courses of COPAD chemotherapy in children and adolescents with resected localized B‐cell non‐Hodgkin’s lymphoma: results of the FAB/LMB 96 international study * , 2008, British journal of haematology.
[36] S. Perkins,et al. Results of the randomized international FAB/LMB96 trial for intermediate risk B-cell non-Hodgkin lymphoma in children and adolescents: it is possible to reduce treatment for the early responding patients. , 2007, Blood.
[37] S. Perkins,et al. Results of a randomized international study of high-risk central nervous system B non-Hodgkin lymphoma and B acute lymphoblastic leukemia in children and adolescents. , 2007, Blood.
[38] N. Tarbell,et al. Advanced-stage large-cell lymphoma in children and adolescents: results of a randomized trial incorporating intermediate-dose methotrexate and high-dose cytarabine in the maintenance phase of the APO regimen: a Pediatric Oncology Group phase III trial. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[39] B. Burkhardt,et al. The impact of the methotrexate administration schedule and dose in the treatment of children and adolescents with B-cell neoplasms: a report of the BFM Group Study NHL-BFM95. , 2004, Blood.
[40] M. Orjuela,et al. A pilot study of chemoimmunotherapy (cyclophosphamide, prednisone, and rituximab) in patients with post-transplant lymphoproliferative disorder following solid organ transplantation. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.
[41] P. Papenhausen,et al. Burkitt Lymphoma Arising in Organ Transplant Recipients: A Clinicopathologic Study of Five Cases , 2003, The American journal of surgical pathology.
[42] Pierre Morel,et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. , 2002, The New England journal of medicine.
[43] S. Murphy. Classification, staging and end results of treatment of childhood non-Hodgkin's lymphomas: dissimilarities from lymphomas in adults. , 1980, Seminars in oncology.